Provided by Tiger Fintech (Singapore) Pte. Ltd.

GlaxoSmithKline PLC

37.97
-0.2600-0.68%
Post-market: 37.80-0.1700-0.45%19:53 EDT
Volume:4.02M
Turnover:151.75M
Market Cap:76.69B
PE:19.30
High:37.97
Open:37.71
Low:37.51
Close:38.23
Loading ...

GSK PLC (GSK) Q1 2025 Earnings Call Highlights: Strong Specialty Medicines Growth Amid Vaccine ...

GuruFocus.com
·
01 May

GSK Announces Total Voting Rights and Capital Structure Update

TIPRANKS
·
01 May

GSK says Nucala delivers clinically meaningful reduction in COPD exacerbations

TIPRANKS
·
01 May

GSK (LSE:GSK) Sees First Quarter Sales of £7.5 Billion and Net Income Surge

Simply Wall St.
·
01 May

GSK Rises Wednesday, Outperforms Market

Dow Jones
·
01 May

European Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday Trading

MT Newswires Live
·
30 Apr

Tariff turmoil prompts cloudy forecasts from companies for the year ahead

Associated Press Finance
·
30 Apr

Earnings Movers | Snap Plunges 17%; Norwegian Cruise Tumbles 11%; Tenable and First Solar Sink 10%; Starbucks Drops 7%

Tiger Newspress
·
30 Apr

GlaxoSmithKline (GSK) Gets a Hold from UBS

TIPRANKS
·
30 Apr

Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales

Benzinga
·
30 Apr

Pre-Bell|U.S. Futures Drop After ADP and GDP Datas; Super Micro Plunges 19%; Snap Tumbles 15%; Starbucks Sinks 10%

Tiger Newspress
·
30 Apr

Jefferies Remains a Hold on GlaxoSmithKline (GSK)

TIPRANKS
·
30 Apr

GSK (GSK) Q1 Earnings Surpass Estimates

Zacks
·
30 Apr

GSK Q1 Core Earnings, Revenue Increase

MT Newswires Live
·
30 Apr

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

Dow Jones
·
30 Apr

GSK Affirms Its FY25 Guidance And Expects Its Turnover To Increase Between 3%-5% And Core Operating Profit To Increase Between 6%-8%. Core EPS Is Expected To Increase Between 6%-8%

Benzinga
·
30 Apr

J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

TIPRANKS
·
30 Apr

GSK Q1 Adj. EPS $1.13 Beats $1.04 Estimate, Sales $9.46B Beat $7.46B Estimate

Benzinga
·
30 Apr

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

Dow Jones
·
30 Apr

GSK plc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
30 Apr